About MS  > MS news and research  > Drugs  > ATL1102
About MS

What is MS?

MS symptoms

Managing your MS

Effects of MS

MS news and research

Bacteria and viruses

Biomarkers and microRNA

CCSVI

Cognition

Diet

Drugs

Ampyra (Fampyra)

ATL1102

Aubagio

Betaferon (Betaseron)

Cannabis and cannabinoids

Copaxone, Glatopa and glatiramer acetate

Emerging therapies

Gilenya

Low dose naltrexone

Lemtrada (alemtuzumab)

Masitinib

MIS416

MN-166 (ibudilast)

Nerventra® (laquinimod)

Ocrelizumab

Plegridy (peginterferon beta-1a)

RPC1063

Sativex

Statins

Tcelna

Tecfidera

Tysabri

Zenapax (daclizumab)

Endo-parasites and helpful organisms

Environmental factors

Ethnic groups, geographical regions and MS

Exercise

Genetics

Hormones

Immune cells

Inflammation, lesions & 'black holes'

Medical imaging

MS Symptoms research

Multiple Sclerosis (etiology)

Myelin

Nerves, brain cells and spinal cord

Paediatric MS

Pain

Potential viral causes

Quality of life

Retroviruses

Sex and MS

Stem cells

Technology

Types of MS

Vaccinations

Vitamin D

World MS Day

News and research archive

Other support

Donate with JustGiving

Latest Tweets

ATL1102

 

New Phase IIb trial of potential MS drug ATL1102 given go ahead(29/10/14)

A new human clinical trial testing the drug ATL1102 to treat Multiple Sclerosis was approved by FDA, carrying the promise of new therapeutics to affected patients.

Antisense Therapeutics Limited (ANP) announced recently in a press release the FDA’s positive decision to approve their request to submit an Investigational New Drug (IND) application in the U.S. This decision allows ANP to initiate a long-term Phase IIb clinical trial for the treatment of Multiple Sclerosis (MS) with ATL1102.

ANP is currently looking for a pharmaceutical partner for the ATL1102 program development.

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. Currently without a cure, MS affects more than 2.3 million people worldwide, 300,000 to 400,000 of whom live in the United States alone. The disease is characterised by destruction of myelin layer within nerve cells, probably caused by a hyper-reactive immune system, with accumulation of white blood cells (leukocytes) in the central nervous system. This leads to a wide range of neurological symptoms affecting visual, motor, and sensory capabilities.

ATL1102 is an antisense inhibitor (belonging to the second generation of inhibitors) of CD49d, a subunit of VLA-4 (Very Late Antigen-4) and a key player regulating immune cell recruitment to inflamed endothelia and other sites of inflammation. Thus, inhibiting VLA-4 potentially prevent leukocytes recruitment, delaying disease progression. VLA-4 is a clinically validated target in the treatment of MS.

ANP showed previously that ATL1102 effectively reduced MS lesions in a Phase II clinical trial in patients with relapsing-remitting multiple sclerosis (RRMS), with superior results when compared to Tysabri® (natalizumab), a monoclonal antibody drug to the VLA-4 receptor. While Tysabri® was reported to cause a potential lethal viral brain infection (progressive multi focal leukoencephalopathy, PML), ATL1102 was safer and equally effective.

Antisense Therapeutics’ CEO and Managing Director Mark Diamond commented, “The FDA Response is an excellent outcome and important step in moving ATL1102 forward into late-stage clinical development and to capitalize on the substantial development and investment made to date on this key project asset. We look forward to providing further updates as we advance development and commercialisation plans for this exciting new therapeutic to treat MS.”

Source: Multiple Sclerosis News T oday © Copyright 2014 BioNews Services, LLC (29/10/14)

Phase IIa clinical trial data of ATL1102 in MS patients published(22/09/14)

Antisense Therapeutics reports the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

The article titled “CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS”, is currently available online and will be included in the print edition Volume 83, November 11, 2014.

The article highlights the successful outcomes of the Phase IIa clinical trial of ATL1102 in Multiple Sclerosis (MS) patients where in the randomised, double-blind, placebo-controlled study in 77 patients with relapsing-remitting multiple sclerosis (RRMS), ATL1102 met its primary end point after only two months of dosing, showing a significant reduction, by 54.4% (p=0.01) in the cumulative number of new active brain lesions in patients taking ATL1102 compared to placebo.

The efficacy outcomes from this study were viewed to be as good as, or superior to, those achieved with MS drug Tysabri® at a similar stage in its clinical development. Tysabri® (natalizumab) is a monoclonal antibody drug targeting the VLA-4 receptor (same target as ATL1102). In 2013, Tysabri® generated sales in excess of US$1.6 billion. It is regarded as the current efficacy benchmark for the treatment of RRMS. ANP anticipates that ATL1102 could be as potent as Tysabri® but potentially safer, cheaper to manufacture, and more conveniently dosed.

Principal Investigator of the ATL1102 Phase IIa study and lead author of the Neurology publication, Volker Limmroth (MD PhD Professor of Neurology, Chairman Department of Neurology and Palliative Care Medicine Cologne City Hospitals, University of Cologne) said:

There are a number of unresolved issues with current MS drugs including the occurrence of neutralising antibodies to the antibody, protein and peptide MS drugs as well as long-term safety concerns with the more recently approved drugs. There is a clear need for more effective and safe drugs for the significant population of MS patients who have relapses and non-stable disease.

The ATL1102 Phase IIa trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders such as MS. ATL1102 was shown to be highly effective in reducing brain lesions in RRMS patients with a quick onset of action and a clinical safety profile that strongly supports its ongoing development as a treatment for this disease.

The full article can be downloaded from http://www.neurology.org/content/early/recent 

Antisense Therapeutics CEO and Managing Director Mark Diamond said:

The Journal of the American Academy of Neurology is the most widely read and highly cited peer-reviewed Neurology Journal. Having our ATL1102 Phase II data published in such a high quality scientific journal is extremely beneficial for the future development and partnering plans for the drug and our current FDA interactions. It also provides further independent validation to the quality of our data and considerable development progress made by the Company in advancing ATL1102.

Source: News-Medical.Net Copyright 2000-2014 AZoM.com Limited (22/09/14)